Lead Product(s) : Tempol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Adamis Announces Review of Strategic Alternatives
Details : Tempol (MMB-02) capsule, is a redox cycling nitroxide in development for the treatment of patients with COVID-19, was the subject of a Phase 2/3 clinical trial which has been halted.
Product Name : Tempol
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 03, 2022
Lead Product(s) : Tempol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tempol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects
Details : This trial did not meet its primary endpoint, but we are exploring the possibility that vaccinations and the less virulent variants (Omicron) during the trial period may have obscured an effect of Tempol (MMB-02).
Product Name : Tempol
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 21, 2022
Lead Product(s) : Tempol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tempol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tempol (MMB-02) is a redox cycling nitroxide that promotes the metabolism of many reactive oxygen species and improves nitric oxide bioavailability. It has been studied extensively in animal models of oxidative stress and inflammation.
Product Name : Tempol
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 12, 2022
Lead Product(s) : Tempol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tempol
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Treatment of Metastatic Cancer in Terminally Diagnosed Patients
Details : Tempol is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 08, 2022
Lead Product(s) : Tempol
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tempol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Stanford University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The results of published study suggesting that MMB-02 (tempol) Capsule has strong, broad in-vitro anti-cytokine activity. Suppression of inflammatory cytokines with an antioxidant may be a beneficial treatment strategy in early COVID-19 infection.
Product Name : Tempol
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 01, 2022
Lead Product(s) : Tempol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Stanford University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tempol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Galveston National Laboratory
Deal Size : Inapplicable
Deal Type : Inapplicable
Adamis Pharmaceuticals Announces Results of Tempol in Omicron Virus Challenge in Hamster Model
Details : Hamsters challenged with high levels of the Omicron variant of the SARS-CoV-2 virus, resulted in a significant decrease in inflammation in the lungs of animals treated with Tempol (MBM-02), a novel antioxidant, compared to controls.
Product Name : Tempol
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 22, 2022
Lead Product(s) : Tempol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Galveston National Laboratory
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tempol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data Safety Monitoring Board met to evaluate interim clinical and safety data and clears, from the first planned interim analysis Phase 2/3 study to continue for Tempol, for the treatment of COVID-19.
Product Name : Tempol
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 14, 2022
Lead Product(s) : Tempol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tempol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : As part of the initial phase 2 portion of the study, 50 COVID positive subjects with comorbidities will be enrolled. Eligible subjects positively diagnosed COVID-19 infection will be randomized 1:1 to receive either Tempol or placebo.
Product Name : Tempol
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 28, 2022
Lead Product(s) : Tempol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tempol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preclinical studies of Tempol have shown it to have antiviral, anti-inflammatory, and antioxidant activity. The Company believes this unique mechanism of action, combined with the benign safety profile shown in preclinical and ongoing clinical studies.
Product Name : Tempol
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 07, 2022
Lead Product(s) : Tempol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tempol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Human Immune Monitoring Center at Stanford University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tempol, a novel antioxidant is currently being studied in a Phase 2/3 clinical trial in adult patients with confirmed COVID-19 infection, used in the treatment of a patient with respiratory diseases including asthma, respiratory syncytial virus, influenz...
Product Name : Tempol
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 10, 2022
Lead Product(s) : Tempol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Human Immune Monitoring Center at Stanford University
Deal Size : Inapplicable
Deal Type : Inapplicable